Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 9-13 |
| Number of pages | 5 |
| Journal | OncoTargets and Therapy |
| Volume | 12 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Pain
- Prostate cancer
- Radioactive therapy
- Radium-223
Cite this
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. / Roviello, Giandomenico; Gallicchio, Rosj; Bozza, Giovanni; Rodriquenz, Maria Grazia; Aieta, Michele; Storto, Giovanni.
In: OncoTargets and Therapy, Vol. 12, 01.01.2019, p. 9-13.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
AU - Roviello, Giandomenico
AU - Gallicchio, Rosj
AU - Bozza, Giovanni
AU - Rodriquenz, Maria Grazia
AU - Aieta, Michele
AU - Storto, Giovanni
PY - 2019/1/1
Y1 - 2019/1/1
N2 - © 2019 Roviello et al. Background: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. Patients and methods: Patients with histologically confirmed progressive CRPC with two or more bone metastases and symptomatic disease were eligible. Previous therapy with a novel hormonal therapy was allowed. The patients received six intravenous injections of radium-223 every 4 weeks. A visual analog scale (VAS) was adopted to evaluate patients’ basal pain. Results: A total of 25 patients were evaluated. Of these, 6 (24%) reported VAS,4. After a median follow-up of 8 months, all patients died with a median overall survival of 8.3 months (95% CI: 5.2–11.8 months), 12.6 months in the patients with VAS,4 vs 6.6 months in the patients with VAS $4 (P=0.03). Conclusion: The present study suggests that VAS could be prognostic of the survival of mCRPC treated with radium-223 irrespective of the limitations of a small number of patients and the retrospective nature of the data.
AB - © 2019 Roviello et al. Background: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. Patients and methods: Patients with histologically confirmed progressive CRPC with two or more bone metastases and symptomatic disease were eligible. Previous therapy with a novel hormonal therapy was allowed. The patients received six intravenous injections of radium-223 every 4 weeks. A visual analog scale (VAS) was adopted to evaluate patients’ basal pain. Results: A total of 25 patients were evaluated. Of these, 6 (24%) reported VAS,4. After a median follow-up of 8 months, all patients died with a median overall survival of 8.3 months (95% CI: 5.2–11.8 months), 12.6 months in the patients with VAS,4 vs 6.6 months in the patients with VAS $4 (P=0.03). Conclusion: The present study suggests that VAS could be prognostic of the survival of mCRPC treated with radium-223 irrespective of the limitations of a small number of patients and the retrospective nature of the data.
KW - Pain
KW - Prostate cancer
KW - Radioactive therapy
KW - Radium-223
UR - http://www.scopus.com/inward/record.url?scp=85059448933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059448933&partnerID=8YFLogxK
U2 - 10.2147/OTT.S174206
DO - 10.2147/OTT.S174206
M3 - Article
AN - SCOPUS:85059448933
VL - 12
SP - 9
EP - 13
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
SN - 1178-6930
ER -